GLP-1 plus B12 for weight loss and hormones: what checks out

What did @love_maryscott actually say?

She said she's been taking a GLP-1 since September 2022, that her current formulation comes from a telehealth provider called LMD and includes B12 mixed in. She walked viewers through a subcutaneous injection in the back of her arm, mentioned she prefers that site over her abdomen because she had a tummy tuck and worries scar tissue affects absorption. In her caption, she attributed 50-plus pounds of weight loss to the shot, along with improvements in hormones, energy, and overall health.

To be clear, what she described in the transcript is mostly a product walkthrough and injection tutorial. The bigger hormonal and energy claims live in the caption, not in what she actually said on camera. That matters, because the verbal claims are more restrained than the written ones.

Does the science back this up?

For weight loss, yes, substantially. The hormonal and energy claims are where things get murkier.

GLP-1 receptor agonists have strong clinical backing for weight reduction. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed semaglutide 2.4mg produced an average 14.9% body weight reduction over 68 weeks. Tirzepatide data from SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed even stronger results, up to 22.5% reduction. Fifty pounds is entirely plausible depending on her starting weight and how long she has been on therapy.

The B12 claim is trickier. Some compounded GLP-1 formulations include B12, theoretically to support energy and reduce fatigue. There is no published randomized trial showing that adding B12 to semaglutide improves weight loss or hormonal outcomes. B12 deficiency does cause fatigue, so if someone was deficient, supplementing could improve energy. But that is correcting a deficiency, not a drug synergy.

The hormone claim is the loosest. Weight loss itself does improve hormonal markers, including insulin sensitivity, testosterone in women with PCOS, and thyroid function in some patients (Churuangsuk et al., 2022, Obesity Reviews). Attributing hormonal changes specifically to the GLP-1 plus B12 combination, rather than to weight loss generally, overstates what the evidence currently supports.

What did they get wrong (or right)?

She got the injection site reasoning mostly right, and she deserves credit for that. The concern about scar tissue from a tummy tuck affecting subcutaneous absorption is clinically reasonable. Fibrotic tissue can impair drug diffusion from the injection depot. There are no large trials specifically on tummy tuck scar tissue and GLP-1 absorption, but the logic tracks with what we know about subcutaneous pharmacokinetics.

She got the injection site options right too. Abdomen, thigh, and upper arm are the three approved sites for subcutaneous GLP-1 injections, consistent with FDA-approved labeling.

What she got wrong, or at least overclaimed: the caption's assertion that the shot produced hormonal improvements is almost certainly conflating GLP-1 effects with the downstream effects of losing 50 pounds. Those are different things. Also, the compounded formulation she is using from LMD is not the same as an FDA-approved GLP-1 medication. Compounded drugs are not FDA-approved and have not gone through the same efficacy and safety review process. That distinction matters and was never mentioned.

What should you actually know?

If you are watching this video and thinking about trying a compounded GLP-1 with B12, there are a few things worth understanding before you order anything.

• Compounded semaglutide or tirzepatide is not the same as Wegovy, Ozempic, Mounjaro, or Zepbound. The FDA has taken action against some compounders for quality and dosing concerns. Ask your provider specifically which compound they are using and whether it has been third-party tested.
• B12 added to GLP-1 injections is common in telehealth compounding, but the evidence base for it improving outcomes is thin. If you are already B12-sufficient, the addition likely does little.
• The hormonal benefits she describes are real, but they are probably a consequence of significant weight loss, not a direct pharmacological effect of the GLP-1 compound itself. That is still meaningful, but the mechanism matters if you are not losing weight and waiting for hormonal benefits that may not arrive.
• Injection site rotation matters. Repeatedly injecting the same spot can cause lipohypertrophy, which does reduce absorption.
• GLP-1 therapy works best alongside behavioral support. The SCALE trial (Pi-Sunyer et al., 2015, NEJM) and STEP trials both included lifestyle counseling. Telehealth platforms vary widely in how much support they actually provide.